Patent ID: 7776822

Claim:
A method of treating a subject with a carcinoma comprising administering to said subject parenterally by infusion or injection a tumoricidally effective amount of a composition consisting of: (i) a native staphylococcal enterotoxin or streptococcal pyrogenic exotoxin protein which native protein: (a) has the biological activity of stimulating T cell mitogensis via a T cell receptor vβ region or (ii) a biologically active homologue or fragment of a native staphylococcal enterotoxin or streptococcal pyrogenic exotoxin, which homologue or fragment: (a) has the biological activity of stimulating T cell mitogenesis via a T cell receptor vβ region and (b) has sequence homology characterized as a z value exceeding 13 when the sequence of the homologue or said fragment is compared to the sequence of a native staphylococcal enterotoxin or a native streptococcal progenic exotoxin, determined by FASTA analysis using gap penalties of -12 and -2, Blosum 50 matrix and Swiss-PROT or PIR database; or (iii) a biologically active fusion protein having said biological activity and said sequence homology, comprising (A) said homologue, (B) a native staphylococcal enterotoxin, (C) a native streptococcal pyrogenic exotoxin, or (D) a biologically active fragment of said homologue, said native enterotoxin or said native exotoxin, fused to a peptide or polypeptide fusion partner, wherein a chemotherapeutic drug or drugs is/are administered parenterally by infusion or injection before, together with or after administration of said enterotoxin or exotoxin composition.